Clinical trials: HCM - Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into circulation.
- Conditions
- Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
- Trial name
- NCT00001534
- Testing
- Losartan
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy, Genetic Disease
Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy
Investigators aim to use comparative exome and/or genome sequencing to discover causative molecular lesions for phenotypes hypothesized to be caused by somatic mutations.
- Conditions
- Hypertrophic Cardiomyopathy, Genetic Disease, Gene Product Sequence Variation
- Trial name
- NCT03043209
- Testing
- Genomic sequencing
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The Cleveland Clinic
Hypertrophic Cardiomyopathy
Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
The primary aim of this study will be to assess whether Biventricular pacing improves exercise capacity, and Quality of Life in patients with symptomatic drug resistant Non-Obstructive Hypertrophic Cardiomyopathy, using a…
- Trial name
- NCT00698074
- Testing
- Cardiac Resynchronisation Therapy
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University Hospital Birmingham
Hypertrophic Cardiomyopathy
A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan
This cross-sectional, non-interventional study will assess health-related quality of life in in patients with hypertrophic cardiomyopathy in Japan. The study consists of two phases.
- Trial name
- NCT06181617
- Testing
- Quality of life assessment
- Where
- Japan
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathies, Athlete Heart
Role of CMR-FT in Assessment of HCM and Athlete's Heart.
Using cardiac MRI feature tracking to asses myocardial motion differences in athlete's heart and discovered hypertrophic cardiomyopathy patients to increase diagnostic accuracy of hypertrophic cardiomyopathy.
- Trial name
- NCT06859827
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sohag University
HOCM, Hypertrophic Obstructive Cardiomyopathy, LVOTO - Left Ventricular Outflow Tract Obstruction
Reverse Remodeling After PTSMA in Severe But Asymptomatic LVOT Obstruction
Patients with HOCM and severe LVOT obstruction can remain asymptomatic while significant cellular and structural changes of the heart (adverse remodeling) may occur preceding heart failure and rhythm disorders.
- Conditions
- HOCM, Hypertrophic Obstructive Cardiomyopathy, LVOTO - Left Ventricular Outflow Tract Obstruction, Remodeling, Ventricular
- Trial name
- RASTA (NCT04230551)
- Testing
- PTSMA
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- St. Antonius Hospital
Cardiomyopathy, Hypertrophic Obstructive
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
This is a randomized, double-blind, placebo-controlled, sequential, 5-day treatment, ascending dose study in subjects with obstructive HCM aged 18-70 years.
- Trial name
- NCT04418297
- Testing
- CT-G20
- Where
- 11 sites in United States, Poland and 1 more
- Volunteers
- 23 people
- Sponsor
- Celltrion
Non-obstructive Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy
Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, is a cause of disability including heart failure, atrial fibrillation, and sudden death, with an annual mortality varying from 1% to 6%.
- Trial name
- CPAPandHCM (NCT01631006)
- Testing
- CPAP
- Where
- Brazil
- Volunteers
- 26 people
- Sponsor
- University of Sao Paulo
Cardiomyopathies, Myocarditis
The Heart Hive - Cardiomyopathy Study
This is an online registry and database of patients with cardiomyopathy and myocarditis, coupled with an observational study of cardiomyopathies.
- Trial name
- NCT04612296
- Testing
- Research genetic analysis
- Where
- United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- Imperial College London
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
- Trial name
- SEQUOIA-HCM (NCT05186818)
- Testing
- Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
- Where
- 114 sites in United States, China and 12 more
- Volunteers
- 282 people
- Sponsor
- Cytokinetics
Apical Hypertrophic Cardiomyopathy
Surgical Treatment of the Patients With Restrictive Phenotype of the Hypertrophic Cardiomyopathy Without LVOT Obstruction
Hypertrophic cardiomyopathy - is an inherited disease characterized by pronounced genetic and phenotypic heterogeneity. There are two most common anatomic variants of cardiac hypertrophy: subaortic and submitral phenotypes.
- Trial name
- NCT06977646
- Testing
- Surgical transaortic left ventricular cavity remodeling in patients with apical hypertrophic cardiomyopathy without left ventricular outflow tract obstruction
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Petrovsky National Research Centre of Surgery
Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Neurologic Evaluation
Neurologic Evaluation of Patients After Transapical Beating-Heart Septal Myectomy
The goal of this prospective cohort study is to evaluate the neurologic changes in patients that received transapical beating-heart septal myectomy.
- Conditions
- Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Neurologic Evaluation, Magnetic Resonance Imaging \(MRI\), Transapical Beating-Heart Septal Myectomy
- Trial name
- NCT06078410
- Testing
- Cardiac surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xiang Wei
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
- Trial name
- MAPLE-HCM (NCT05767346)
- Testing
- Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
- Where
- 71 sites in United States, Brazil and 11 more
- Volunteers
- 175 people
- Sponsor
- Cytokinetics
Hypertrophic Cardiomyopathy
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with…
- Trial name
- NCT06347159
- Testing
- EDG-7500
- Where
- 21 sites in United States
- Volunteers
- 79 people
- Sponsor
- Edgewise Therapeutics, Inc.
Non-obstructive Hypertrophic Cardiomyopathy
A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy
This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with…
- Trial name
- NCT06816251
- Testing
- HRS-1893
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Healthy, Dilated Cardiomyopathy
Molecular and Imaging Studies of Cardiovascular Health and Disease
Biobank is a program which collects biological samples, health information and imaging data from consented patients and stored them at the core facility.
- Conditions
- Healthy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Ischemic Heart Disease
- Trial name
- Biobank (NCT02804269)
- Testing
- Cardiovascular Magnetic Resonance, Fatmass measurement
- Where
- Singapore
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Heart Centre Singapore
Hypertrophic Cardiomyopathy
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
The purpose of this study is to determine whether taking losartan helps people with hypertrophic nonobstructive cardiomyopathy feel better by decreasing the amount of heart muscle thickening and/or the amount of heart muscle…
- Trial name
- NCT01150461
- Testing
- losartan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Hypertrophic Cardiomyopathy, Obstructive
Percutaneous Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy in Children
The primary purpose of this study was to demonstrate the safety and efficacy of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) in children and assessed its performance and functional outcomes in the…
- Trial name
- NCT06540183
- Testing
- Percutaneous intramyocardial septal radiofrequency ablation
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Xijing Hospital
HCM - Hypertrophic Cardiomyopathy
Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR
his is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of Henagliflozin (an SGLT2 inhibitor) on myocardial fibrosis burden in patients with non-obstructive hypertrophic…
- Trial name
- NCT07294495
- Testing
- Henagliflozin (SGLT2 Inhibitor)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai East Hospital
Cardiomyopathy, Hypertrophic, Muscular Dystrophy, Oculopharyngeal
Study of Muscle Abnormalities in Patients With Specific Genetic Mutations
Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease affecting the heart. It causes thickening of heart muscle, especially the chamber responsible for pumping blood out of the heart, the left ventricle.
- Trial name
- NCT00001871
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)